Processing .....please wait.. 
The article has been forwarded.... 
Ranbaxy gets FDA nod for antidepressant
By siliconindia
|
Wednesday, 17 September 2003, 19:30 IST
MUMBAI: Ranbaxy Laboratories has announced that the company has received final approval from the US Food & Drug Administration (USFDA) to market Nefazodone Hydrochloride tablets (50mg, 100 mg, 150 mg, 200 mg and 250 mg.)
According to a release issued to the BSE today, Nefazodone Hydrochloride tablets are indicated for the treatment of depression.
"The product will be made available by Ranbaxy Pharmaceuticals Inc (RPI), a wholly-owned subsidiary of Ranbaxy, under the Ranbaxy label, on a nationwide basis in November," the release said quoting Jim Meehan, vice president (sales & marketing) of RPI
The company had earlier in the day announced the launch of Rosuvas (Rosuvastatin) - the most recent introduction among the drug class of statins.
According to a release issued to the BSE, statins are the most prescribed cholesterol reducing agent across the world.
"Rosuvas is the most aggressive therapy till date for lowering of LDL cholesterol, which also reduced triglycerides and raises HDL. The product has been introduced in India by Ranbaxy CV, the cardiovascular division of Ranbaxy," the release added.